cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Viking Therapeutics Inc
27 own
26 watching
Current Price
$9.96
$0.4
(4.18%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
763.82M
52-Week High
52-Week High
9.96
52-Week Low
52-Week Low
2.02
Average Volume
Average Volume
1.83M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization763.82M
icon52-Week High9.96
icon52-Week Low2.02
iconAverage Volume1.83M
iconDividend Yield--
iconP/E Ratio--
What does the Viking Therapeutics Inc do?
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies for metabolic and endocrine disorders. Its lead clinical program includes VK0612, an orally available drug candidate for the treatment of type 2 diabetes. The company is also developing VK5211, an orally available drug candidate, which is in a Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. In addition, it is developing VK0214, a novel liver-selective thyroid hormone receptor beta agonist for lipid disorders, such as dyslipidemia and nonalcoholic steatohepatitis, as well as VK2809, an orally available, tissue, and receptor-subtype selective agonist of the thyroid beta receptor that is entering Phase II development for the treatment of patients with hypercholesterolemia and fatty liver disease. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
Read More
How much money does Viking Therapeutics Inc make?
News & Events about Viking Therapeutics Inc.
Benzinga
1day ago
read more...
PR Newswire
30days ago
Viking Therapeutics Announces Completion of Enrollment in Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) Viking Therapeutics Announces Completion of Enrollment in Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic...
PR Newswire
1month ago
Thinking about buying stock in AMC Entertainment, TAL Education, Omeros Corp, Acer Therapeutics, or Viking Therapeutics? Thinking about buying stock in AMC Entertainment, TAL Education, Omeros Corp, Acer Therapeutics, or Viking Therapeutics? PR Newswire NEW YORK, Dec. 23, 2022 NEW YORK, Dec. 23...
PR Newswire
1month ago
Thinking about buying stock in Core Scientific, AMC Entertainment, TAL Education, Rivian Automotive, or Viking Therapeutics? Thinking about buying stock in Core Scientific, AMC Entertainment, TAL Education, Rivian Automotive, or Viking Therapeutics? PR Newswire NEW YORK, Dec. 22, 2022 NEW YORK...
PR Newswire
1month ago
Thinking about buying stock in 180 Life Sciences, Viking Therapeutics, Camber Energy, New Oriental Education & Tech, or Rigel Pharmaceuticals? Thinking about buying stock in 180 Life Sciences, Viking Therapeutics, Camber Energy, New Oriental Education & Tech, or Rigel...
Frequently Asked Questions
Frequently Asked Questions
What is Viking Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Viking Therapeutics Inc shares?
plus_minus_icon
How can I buy Viking Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Viking Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Viking Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Viking Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Viking Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Viking Therapeutics Inc?
plus_minus_icon
What percentage is Viking Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Viking Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$9.96
$0.4
(4.18%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation
$2.95
$0.05 (1.72 %)
Cymabay Therapeutics Inc
Cymabay Therapeutics Inc
$8.50
$0.15 (1.80 %)
MARINUS PHARMACEUTICALS INC
MARINUS PHARMACEUTICALS INC
$6.71
$0.22 (3.39 %)
Novavax, Inc.
Novavax, Inc.
$10.89
$-0.20 (-1.80 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation
$2.95
$0.05 (1.72 %)
Cymabay Therapeutics Inc
Cymabay Therapeutics Inc
$8.50
$0.15 (1.80 %)
MARINUS PHARMACEUTICALS INC
MARINUS PHARMACEUTICALS INC
$6.71
$0.22 (3.39 %)
Novavax, Inc.
Novavax, Inc.
$10.89
$-0.20 (-1.80 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00